WHO publishes new AI-Guideline: An important step for the pharmaceutical indutry
Thescon supports innovative AI-applications in the regulated industry
Artificial Intelligence (AI) offers countless innovative applications in various sectors of the economy, especially in the health, pharmaceutical, and medical fields. It is already widely used, such as in the very popular ChatGPT. However, AI also presents new potential dangers and risks for society as well as specifically for companies planning to use it or already using it. This requires a rethinking compared to conventional, non-self-learning, and therefore static systems.
The World Health Organization (WHO) has recognized this and recently, on January 18, 2024, published new guidelines on AI ethics and governance. These guidelines aim to ensure the safe and ethical use of LLMs and focus on a variety of applications, from research and development in the pharmaceutical sector to diagnosis, clinical care, and training of medical professionals.
The WHO points out that the risks of using LLMs can include the generation of erroneous, biased, or incomplete results. To minimize these risks and maximize the benefits of the technology, the WHO emphasizes the importance of collaboration between governments, technology companies, health organizations, and civil society.
At Thescon, we have taken on the challenge of supporting our clients in implementing AI applications in the regulated industry. Our experts, Ingo Baumann and Dr. Cecilia Vallet, are leaders in the development and validation of AI-based systems in the pharmaceutical and medical device sectors. Their work, published in professional journals such as Pharmaceutical Engineering and Manager Wissen, as well as our webinars and podcast discussions in the GMPodcast, offer valuable insights into the world of AI in the pharmaceutical and medical technology sector.
The latest WHO guidelines are an important step towards a safe and ethical future for AI applications in the pharmaceutical industry. Thescon remains at the forefront of SAP validation and is watching the further development of this exciting sector with great interest. We are convinced that this is just the beginning of a far-reaching and productive application of LLMs and AI in general in the pharmaceutical and healthcare sector.
For more information on the WHO guidelines, please visit the official link: https://www.who.int/publications/i/item/9789240084759.
Stay up to date with Thescon on the latest AI developments in the pharmaceutical industry!